3.1 PTUPB reduces blood pressure and lacks anti-diabetic actions
in obese ZSF1 rats
Obese ZSF1 rats were severely diabetic with 60 to 75% higher fasting
blood glucose, increased HbA1c, increased HOMA index, decreased rate of
glucose clearance, and marked hyperinsulinemia compared to lean ZSF1
rats (Figure 1). Neither interventional PTUPB nor enalapril treatment
attenuated hyperglycemia, hyperinsulinemia, and insulin resistance in
obese ZSF1 rats. All markers of overt type 2 diabetes remained markedly
elevated compared to lean ZSF1 rats. The obese ZSF1 rats had increased
body weight (733±11g) compared to lean ZSF1 rats (470±9g), and neither
PTUPB (702±7g) nor enalapril (722±10g) treatments affected body weight
of obese ZSF1 rats. Systolic blood pressure was higher in obese ZSF1
rats (182±7 mmHg) compared to lean ZSF1 rats (139±5 mmHg). In obese ZSF1
rats 8-week PTUPB and enalapril treatments reduced blood pressure. Blood
pressure averaged 161±9 mmHg in PTUPB and averaged 147±10 mmHg in
enalapril treated obese ZSF1 rats.